ANN GROOVER: Open Payments
NPI 1871664995 · CALHOUN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$433,081 in 649 payments from 16 companies in 2025. Trend: 2023 $230,056 · 2024 $197,001 · 2025 $433,081
Speaker / faculty: $323,677Travel & lodging: $66,273Honoraria: $26,326Food & beverage: $11,806Consulting: $5,000
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 328 | $239,188 |
| ABBVIE INC. | 188 | $95,057 |
| Teva Pharmaceuticals USA, Inc. | 37 | $49,556 |
| Axsome Therapeutics, Inc. | 38 | $30,416 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $18,114 |
| Neurocrine BioSciences, Inc. | 8 | $258 |
| Janssen Pharmaceuticals, Inc | 3 | $80 |
| Day One Biopharmaceuticals | 1 | $66 |
| Corium, LLC | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
Products named: FANAPT, VRAYLAR, AUSTEDO XR, Auvelity, CAPLYTA, INGREZZA, INVEGA SUSTENNA, OJEMDA.
Industry payments across GA — which companies pay providers there.
